Compare BLX & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLX | ZYME |
|---|---|---|
| Founded | 1977 | 2003 |
| Country | Panama | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 1997 | 2022 |
| Metric | BLX | ZYME |
|---|---|---|
| Price | $48.19 | $22.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.90 |
| AVG Volume (30 Days) | 108.3K | ★ 630.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.73% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $13.11 | $162.82 |
| Revenue Next Year | $10.13 | N/A |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $31.14 | $9.03 |
| 52 Week High | $51.99 | $28.49 |
| Indicator | BLX | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 43.81 |
| Support Level | $43.50 | $22.23 |
| Resistance Level | $51.60 | $23.66 |
| Average True Range (ATR) | 1.12 | 1.42 |
| MACD | -0.33 | -0.05 |
| Stochastic Oscillator | 33.62 | 9.06 |
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.